Hence, we next examined whether FEN treatment could inhibit the enzymes controlling de novo ceramide synthesis and thus lipotoxicity in the development of NAFLD/NASH in LDLR−/− mice. Here, LDLR is linked to metabolic dysfunction-associated steatotic liver disease.